Emyria has today released its half-year financial report for the period ending 31 December 2023. This report highlights the Company’s substantial progress in becoming a transformative leader and innovator in the evolving space for mental health treatments.
Key highlights include:
- Acquired Pax Centre (Mind Body Consulting Pty Ltd) enhancing clinical service offerings and mental health care capabilities.
- Grew clinical billings for the period to over $2m (Compared to $638k previous period.)
- Secured ethics endorsements for Emyria’s MDMA-Assisted Therapy model and related Authorised Prescriber approval applications (since obtained).
- Commenced dosing in MDMA-assisted therapy trial, supported by successful importation of required drug supply from Canada.
- Implemented Board changes to support the strategic direction of our mental health innovation agenda and in line with our therapeutic and research goals.
- Received favourable review of our MDMA analogue intellectual property claims from international examiner, expediting our future National Phase applications.
- Achieved a critical milestone in the NIH’s fully funded Preclinical Screening Program for Pain with our high-dose CBD capsules (RX7/9), showcasing their therapeutic potential. Program now advanced to Tier 2 screening.
